Essayer OR - Gratuit

Why multi-use real estate is in demand for life sciences companies

BioSpectrum Asia

|

June 2024

India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.

Why multi-use real estate is in demand for life sciences companies

Some of the world’s most iconic resorts, Dubai’s Burj Al Arab for example, are purposefully designed so that guests never really have a reason to leave. There are multiple Michelin stars dotting the names of dozens of restaurants, couture shopping throughout, luxurious amenities around every corner, and boundless options for dazzling entertainment.

While “the world’s only 7-star hotel” isn’t exactly a realistic comparison to an office environment, it does offer inspiration and insight into the demand for mixed-use commercial space. At the end of the day, the average person will spend one-third of their life working. If people are going to allocate roughly 90,000 hours at work, shouldn’t we make the places they go to work a bit more enticing?

Some of the world’s top life sciences, biopharma, R&D, and clinical manufacturing companies think so. India’s Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan’s Daiichi Sankyo, and Singapore’s Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. The reasons for the rise are as vast as the mixed-use amenities the facilities offer, but I think the shift can be summed up in a few key motivations.

Mixed-use commercial space helps companies:

PLUS D'HISTOIRES DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

"The next 5-years will see mRNA science evolve beyond infectious disease"

A new survey from Moderna Singapore reveals persistent vaccine hesitancy among older adults in Singapore, even as international travel and year-end gatherings increase the urgency of protection. The findings point to clear opportunities to strengthen public health, including empowering healthcare professionals as trusted messengers and promoting co-administration of vaccines.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

No Funding No Vax for TB?

The World Health Organization (WHO)'s latest updates on tuberculosis (TB) released on November 12 reveal significant progress in diagnosis, treatment, and political commitment, but also expose deep vulnerabilities—especially in the South-East Asia Region (SEARO)—related to funding gaps and the uncertain future of novel TB vaccines. SEARO remains the global epicentre of the TB epidemic, carrying more than 45 per cent of the world's TB incidence despite representing only a quarter of the global population.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Australia builds tailored heart pump to transform heart failure care

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to heart pump treatments and are left with only medication or palliative care.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Clinical Research Trends 2026: Hybrid DCTs Set for Surge as Innovation Outpaces Regulatory Hurdles

APAC's openness to innovation, combined with its large population and low trial density, creates strong potential for expanding decentralised clinical trials (DCTs), especially for patients with limited trial access. While regulatory diversity and operational challenges will continue to hinder fully decentralised models, the region is expected to adopt more digital technologies in clinical research. As a result, hybrid DCTs will keep gaining traction, and effective management of digitally collected data will remain a central focus for data science teams.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

CSL Seqirus to localise advanced influenza vaccine manufacturing in Saudi Arabia

Australia-based CSL Seqirus and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by accessing advanced cellbased seasonal and pandemic influenza vaccines and localising manufacturing in Saudi Arabia.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

How Sponsors Could Gain Advantage by Embracing Dose Optimisation in Asia by 2026

In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm toward evidence-based dose optimisation. Sponsors might consider adopting strategies similar to the FDA's Project Optimus, which emphasises selecting doses that balance efficacy and safety rather than relying solely on toxicity thresholds. Doing so could improve patient outcomes and position companies favourably as regulatory expectations evolve.

time to read

1 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm launches joint research with National Cancer Center in Japan

Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Monash spinout RAGE Biotech secures $29 M to advance next-generation RNA therapeutics

Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Submitting clinical data to the FDA and PDMA: An efficient and compliant approach

In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications governing submissions for marketing approval of new drugs and biologics. Fortunately, despite some differences, the regulations concerning clinical data have a surprising amount in common. It is possible that with a solid understanding of the requirements and an adherence to best practices, sponsors can develop some of the same material for submission to both countries.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Regenerative medicines and microbiome health are emerging as exciting frontiers, with Australian companies and researchers pushing into new therapeutic approaches

After more than a year at the helm of AusBiotech, CEO Rebekah Cassidy reflects on her early priorities and the organisation’s ambitions as Australia accelerates its position in the global life sciences economy. In an email interaction on the sidelines of AusBiotech 2025, she highlights the country's progress in mRNA, cell and gene therapy, and radiopharmaceuticals, outlines emerging areas of momentum, and discusses how new partnerships and MoUs are strengthening collaboration across the biotech ecosystem. Rebekah also outlines how AusBiotech is preparing Australia for a more competitive and connected global life sciences economy and the strategic priorities shaping AusBiotech’s next chapter. Edited excerpts:

time to read

7 mins

BioSpectrum Asia Dec 2025

Listen

Translate

Share

-
+

Change font size